Loading icon
Press enter or spacebar to select a desired language.
Research
Press enter or spacebar to select a desired language.

PubMed COVID-19 Clinical Care

4221 - 4230 of 44782 results found

One-year follow-up of the immunogenicity and safety of a primary series of the NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults: Final report of a phase I/II randomized controlled trial

Date
Saturday, February 03, 2024 - 4:00 AM
Description
BACKGROUND: In the interim report of this phase I/II randomized, placebo-controlled trial in Japanese adults, a two-dose primary series of NVX-CoV2373 (5 µg SARS-CoV-2 recombinant nanoparticle spike protein [rS]; 50 µg Matrix-M) administered 21 days